Fri, August 10, 2012
Thu, August 9, 2012
Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012

Sarepta Therapeutics to Present Company Overview at the Wedbush PacGrow Life Sciences Management Access Conference


//health-fitness.news-articles.net/content/2012/ .. -life-sciences-management-access-conference.html
Published in Health and Fitness on Monday, July 30th 2012 at 13:19 GMT by Market Wire   Print publication without navigation


July 30, 2012 16:05 ET

Sarepta Therapeutics to Present Company Overview at the Wedbush PacGrow Life Sciences Management Access Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwire - Jul 30, 2012) - Sarepta Therapeutics (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference in New York, NY on Tuesday, August 14, 2012 at 2:30 p.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

The presentation will be webcast live under the events section of Sarepta Therapeutics' website at [ www.sareptatherapeutics.com ] and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources